TITLE

Pharmacokinetics of N-Acetylprocainamide

AUTHOR(S)
Atkinson Jr., Arthur J.; Ruo, Tsuen Ih
PUB. DATE
December 1986
SOURCE
Angiology;Dec1986 Part 2, Vol. 37 Issue 12, p959
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Shortly after Dreyfus and his colleagues demonstrated that procainamide was metabolized by acetylation to N-acetylprocainamide (NAPA),1 Drayer, Reidenberg and Sevy reported that NAPA had antiarrhythmic activity in an animal model.2 We confirmed these findings and found that plasma levels of NAPA were high enough to warrant consideration in managing patients requiring procainamide therapy.3 However, the actual impetus for developing NAPA as an antiarrhythmic drug in its own right was provided by the initial studies of NAPA pharmacokinetics in normal subjects.4 In these studies, we showed that NAPA has an elimination-phase half-life that is more than twice as long as procainamide and suggested that patient compliance and arrhythmia suppression might be improved if NAPA were used to circumvent the inconvenience of the frequent dosing schedule that has been recommended for procainamide.5 From the standpoint of managing individual patients with NAPA, the pharmacokinetics of this drug continue to provide the scientific basis for designing dose regimens that will have maximal antiarrhythmic efficacy and minimal toxicity. This review summarizes the salient features of NAPA pharmacokinetics and outlines an approach for individualizing therapy with this drug.
ACCESSION #
16364874

 

Related Articles

  • Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Takahashi, H.; Echizen, H. // Pharmacogenomics Journal;2003, Vol. 3 Issue 4, p202 

    Summarizes clinical data on the relation between the CYP2C9 polymorphisms and the daily dose requirement of warfarin as well as the susceptibility to bleeding complications, and the impact of CYP2C9 polymorphisms on the pharmacokinetics of (S)-warfarin in different populations. Introduction to...

  • Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Li-mei Han; Jie Guo; Li-jun Zhang; Qing-song Wang; Xiao-ling Fang // Acta Pharmacologica Sinica;Jun2006, Vol. 27 Issue 6, p747 

    Aim: To investigate the preparation, in vitro release, in vivo pharmacokinetics and tissue distribution of a novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic P123. Methods: The polymeric micelles of paclitaxel with Pluronic P123 were prepared by a solid dispersion method....

  • Pharmacokinetics. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p495 

    A definition of the term "pharmacokinetics" is presented. It refers to the study of bodily absorption, distribution, metabolism, and excretion of drugs.

  • Zero-order Kinetic.  // Encyclopedic Reference of Molecular Pharmacology;2004, p1017 

    A definition of the term "Zero-order Kinetic" is presented. It refers to the time course of disappearance of drugs from the plasma, which do not follow an exponential pattern, but are initially linear. This rare time course of elimination is most often caused by saturation of the elimination...

  • Pharmacokinetics and Biotransformation of Mirtazapine in Human Volunteers. Delbressine, L.P.C.; Moonen, M.E.G.; Kaspersen, E.M.; Wagenaars, G.N.; Jacobs, P.L.; Timmer, C.J.; Paanakker, J.E.; van Hal, H.J.M.; Voortman, G. // Clinical Drug Investigation;1998, Vol. 15 Issue 1, p45 

    This paper investigated the pharmacokinetics and biotransformation of mirtazapine in healthy human volunteers. The results showed that the area under the plasma drug concentration- time curve (AUC ) of mirtazapine in human plasma appeared to be three times higher than the AUC of...

  • Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. Pavithra, B. H.; Prakash, N.; Jayakumar, K. // Journal of Veterinary Science;2009, Vol. 10 Issue 4, p293 

    investigation was carried out in adult New Zealand white rabbits to study the influence of curcumin pre-treatment on pharmacokinetic disposition of norfioxacin following single oral administration. Sixteen rabbits were divided into two groups of eight each consisting of either sex. Animals in...

  • A Perspective on Reconciling Mass Balance in Forced Degradation Studies. Lukulay, Patrick; Hokanson, Gerard // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p106 

    Focuses on two scenarios that demonstrate the need to use the percent of parent drug loss rather than the percent of degradation products formed when reconciling mass balance calculations. Quality control check on analytical methods to show that all degradation products are adequately detected...

  • Application of Scaling Factors in Simultaneous Modeling of Microarray Data from Diverse Chips. Zhenling Yao; Baiteng Zhao; Eric Hoffman; Svetlana Ghimbovschi; William Jusko // Pharmaceutical Research;Apr2007, Vol. 24 Issue 4, p643 

    AbstractPurpose??Microarrays have been utilized in many biological, physiological and pharmacological studies as a high-throughput genomic technique. Several generations of Affymetrix GeneChip?microarrays are widely used in gene expression studies. However, differences in intensities of signals...

  • Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. Guti‚rrez, Lilia; Velasco, Zazil-Ha; V zquez, Carlos; Vargas, Dinorah; Sumano, H‚ctor // Acta Veterinaria Scandinavica;2012, Vol. 54 Issue 1, p35 

    Based on its PK/PD ratios, doxycycline hyclate (DOX-h), a time-dependant antibacterial, is ideally expected to achieve both sustained plasma drug concentrations at or slightly above the MIC level for as long as possible between dosing intervals. Pursuing this end, a poloxamer-based matrix was...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics